Ascendis Pharma (ASND) option IV flat as share price up 19.8%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- S&P 500, Dow on course for slim gains at open as Iran tensions clash with AI optimism
- Oil retreats from one-month high as traders weigh supply risks
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
Ascendis Pharma (ASND) PT Raised to $205 at Evercore ISI
September 17, 2024 6:32 AM EDTEvercore ISI analyst Josh Schimmer raised the price target on Ascendis Pharma (NASDAQ: ASND) to $205.00 (from $191.00) while maintaining a Outperform rating.
The analyst comments "Were still refining some estimates via HCP calls. For now, we model $450M peak TransCON CNP sales in achon. For... More
Ascendis Pharma (ASND) PT Raised to $179 at Jefferies
September 16, 2024 4:35 PM EDTJefferies analyst Kelly Shi raised the price target on Ascendis Pharma (NASDAQ: ASND) to $179.00 (from $174.00) while maintaining a Buy rating.
The analyst comments "Co reported pivotal data from Navepegritide (TransCon CNP) in children w/ achondroplasia aged 2-11yo, which showed an... More
